

je však potřeba cíleně rozlišit suplementaci od supresivní léčby aktivním vitamínem D s cílem léčby SHPT. Obě cesty, suplementaci i supresi, lze opatrně kombinovat (31).

Při zpětném ohlédnutí lze konstatovat, že podrobné a skutečně velmi početné studie mnoha vědeckých týmů nás přivedly k současnému již velmi podrobným poznatkům o SHPT při selhání ledvin a jejich souvislostech včetně moderní farmakoterapie, a rozšířily poznatky o dalších kostních změnách, včetně těch, které se selháním ledvin nemusí nijak souviset. Přesto problém kostního onemocnění a jeho důsledků pro celý organismus přetrvává. K příčinám patří velmi složitá

patogeneze i terapeutická úskalí a je nepochybné, že téma zůstává stále velmi aktuální.

*Podpořeno programy MZ ČR – RVO (FNHK, 00179906) a PROGRES Q40/14*

*Poděkování: Autoři děkují kolegům z Radiologické kliniky FN Hradec Králové za cenné vyšetření zobrazovacími metodami (přednosta prof. MUDr. Antonín Krajina, CSc.), kolegům z Kliniky otorinolaryngologie a chirurgie hlavy a krku za vynikající spolupráci v programu parathyreidektomií (přednosta prof. MUDr. Viktor Chrobok, CSc., Ph.D.).*

## LITERATURA

- Moe S, Drüeke T, Cunningham J et al. Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int* 2006; 69(11): 1945–1953.
- Ketteler M, Block GA, Evenepoel P et al. Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update. *Ann Intern Med*. 2018; 168(6): 422–430.
- Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. *Clin J Am Soc Nephrol* 2011; 6: 913–921.
- Cannata-Andía JB, Martín-Carro B, Martín-Vírgala J et al. Chronic Kidney Disease-Mineral and Bone Disorders: Pathogenesis and Management. *Calcif Tissue Int* 2021; 108: 410–422.
- Jørgensen HS, David K, Salam S. et al. European Renal Osteodystrophy (EUROD) workgroup, an initiative of the CKD-MBD working group of the ERA-EDTA. Traditional and Non-traditional Risk Factors for Osteoporosis in CKD. *Calcif Tissue Int*. 2021; 108: 496–511.
- Evenepoel P, Cunningham J, Ferrari S et al. European Renal Osteodystrophy (EUROD) workgroup, an initiative of the CKD-MBD working group of the ERA-EDTA, and the committee of Scientific Advisors and National Societies of the IOF. European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D. *Nephrol Dial Transplant*. 2021; 36: 42–59.
- Vilaca T, Salam S, Schini M et al. Risks of Hip and Nonvertebral Fractures in Patients with CKD G3a-G5D: A Systematic Review and Meta-analysis. *Am J Kidney Dis*. 2020; 76: 521–532.
- Hampson G, Elder GJ, Cohen-Solal M et al. Abrahamsen B. A review and perspective on the assessment, management and prevention of fragility fractures in patients with osteoporosis and chronic kidney disease. *Endocrine*. 2021 May 11. doi: 10.1007/s12020-021-02735-9.
- Brunerova L, Palicka V, Dusilova Sulkova S. Commentary on Management of Osteoporosis in Advanced CKD: Common View of a Nephrologist and a Bone Specialist. *Endocrine Practice* 2019; 25: 193–196.
- Blaine J, Chonchol M, Levi M. Renal control of calcium, phosphate, and magnesium homeostasis. *Clin J Am Soc Nephrol* 2015; 10: 1257–1272.
- Tatsumi S, Miyagawa A, Kaneko I et al. Regulation of renal phosphate handling: inter-organ communication in health and disease. *J Bone Miner Metab*. 2016; 34: 1–10.
- Ureña-Torres PA, Vervloet M, Mazzaferro S et al. ERA-EDTA CKD-MBD Working Group. Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease. *Clin Kidney J* 2018; 12: 269–280.
- Bover J, Arana C, Ureña P et al. Hyporesponsiveness or resistance to the action of parathyroid hormone in chronic kidney disease. *Nefrologia (Engl Ed)*. 2021; doi: 10.1016/j.nefro.2020.12.019.
- Goto S, Fuji H, Hamada Y et al. Association between indoxyl sulphate and skeletal resistance in hemodialysis patients. *Ther Apher Dial*. 2010; 14: 417–423.
- Watanabe K, Tominari T, Hirata M et al. Indoxyl sulphate, a uremic toxin in chronic kidney disease, suppresses both bone formation and bone resorption. *FEBS Open Bio*. 2017; 20(7): 1178–1185.
- Yamamoto S, Fukagawa M. Uremic Toxicity and Bone in CKD. *J Nephrol*. 2017; 30: 623–627.
- Hu MC, Shi M, Zhang J et al. Klotho deficiency causes vascular calcification in chronic kidney disease. *J Am Soc Nephrol* 2011; 22: 124–136.
- Gracioli FG, Neves KR, dos Reis LM et al. Phosphorus overload and PTH induce aortic expression of Runx2 in experimental uraemia. *Nephrol Dial Transplant*. 2009; 24: 1416–1421.
- Schlieper G, Schurgers L, Brandenburg V et al. Vascular calcification in chronic kidney disease: an update. *Nephrol Dial Transplant* 2015.
- Gracioli FG, Neves KR, dos Reis LM et al. Phosphorus overload and PTH induce aortic expression of Runx2 in experimental uraemia. *Nephrol Dial Transplant*. 2009; 24: 1416–1421.
- Carrillo-Lopez N, Panizo S, Alonso-Montes C et al. High serum phosphate and parathyroid hormone distinctly regulate bone loss and vascular calcifications in experimental chronic kidney disease. *Nephrol Dial Transplant* 2018; 34: 934–941.
- Razzaque MS. The dualistic role of vitamin D in vascular calcifications. *Kidney Int*. 2011; 79: 708–714.
- Dusilová Sulková S, Horáček J, Vykoukalová E et al. Parathyroidectomy in Hyperparathyroidism-Associated Calciphylaxis in End-Stage Renal Disease Should be Prompt and Radical – a Case Report with Two Original Therapeutic Modifications and Successful Outcome. *Acta Medica (Hradec Kralove)*. 2017; 60: 85–88.
- Duque EJ, Elias RM, Moyses RMA. Parathyroid Hormone: A Uremic Toxin. *Toxins (Basel)*. 2020; 12:189. doi: 10.3390/toxins12030189.
- Silver J, Naveh-Many T. FGF-23 and secondary hyperparathyroidism in chronic kidney disease. *Nat Rev Nephrol* 2013; 9: 641–649.
- Ketteler M, Ambühl P. Where are we now? Emerging opportunities and challenges in the management of secondary hyperparathyroidism in patients with non-dialysis chronic kidney disease. *J Nephrol*. 2021; doi: 10.1007/s40620-021-01082-2.
- Komaba H, Ketteler M, Cunningham J et al. Old and New Drugs for the Management of Bone Disorders in CKD. *Calcif Tissue Int*. 2021; 108: 486–495.
- Shutto Y, Shimada M, Kitajima M et al. Lack of awareness among future medical professionals about the risk of consuming hidden phosphate-containing processed food and drinks. *PLoS One*. 2011; 6: e29105.
- D'Alessandro C, Piccoli GB, Cupisti A. The “phosphorus pyramid”: a visual tool for dietary phosphate management in dialysis and CKD patients. *BMC Nephrol*. 2015; 16: 9.
- Christodoulou M, Aspray TJ, Schoenmakers I. Vitamin D Supplementation for Patients with Chronic Kidney Disease: A Systematic Review and Meta-analyses of Trials Investigating the Response to Supplementation and an Overview of Guidelines. *Calcif Tissue Int*. 2021 Apr 25. doi: 10.1007/s00223-021-00844-1.
- Sista SK, Arum SM. Management of adynamic bone disease in chronic kidney disease: A brief review. *J Clin Transl Endocrinol* 2016; 5: 32–35.
- Dusilová-Sulková S, Šafránek R, Vávrová J et al. Low-dose cholecalciferol supplementation and dual vitamin D therapy in haemodialysis patients. *Int Urol Nephrol* 2015; 47: 169–176.
- Hu MC, Kuro-o M, Moe OW. The emerging role of Klotho in clinical nephrology. *Nephrol Dial Transplant* 2012; 27(7): 2650–2657.
- Drueke TB, Massy ZA. Changing bone patterns with progression of chronic kidney disease. *Kidney Int* 2016; 89(2): 289–302.